Our patent portfolio covers over 300M diabetics, a very easy to understand addressable market in the tens of billions. NASDAQ listed Renalytix trading at ~1B market cap. Richard said openly at the AGM he believes we heavily undervalued (yes all CEO's say that) but when you look at the fundamentals here, it's a head scratcher why we aren't over $2 yet.
My hope is once revenues from PormarkerD materialize into our quarterly reports, the pudding is then proven and the market will see the underlying investment opportunity here. Best in class product, patent protected moat, win win for everyone from patient to insurers , HCP's, governments & shareholders.
The long termers here have been supporting and backing the company for over 4years now, back when this was trading at 20c! It's been a long journey so far and so much more to come! Stay patient, and GLTAH!
PIQ Price at posting:
$1.19 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)